Headline News

 

Novartis Kesimpta demonstrates benefits in recently diagnosed treatment for individuals with relapsing multiple sclerosis

Posted on April 18, 2024

Roche’s OCREVUS demonstrates near complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Posted on April 18, 2024

Lilly’s Tirzepatide reduces sleep apnea severity by two-thirds in adults with obstructive sleep apnea and obesity

Posted on April 17, 2024

Merck officially launches their first all-in-one genetic stability assay to accelerate biosafety testing

Posted on April 17, 2024

Roche granted FDA breakthrough device designation for their blood test which supports earlier Alzheimer’s disease diagnosis

Posted on April 15, 2024

Roche’s Columvi meets primary endpoints in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

Posted on April 15, 2024

Serum Institute of India and Univercells collaborate to bring affordable and personalized oncology

Posted on April 15, 2024

Ascend acquires GMP manufacturing capacity in Florida and further enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production

Posted on April 15, 2024

Nipocalimab unique molecular properties enables potential in treating generalized myasthenia gravis

Posted on April 15, 2024

Findings at ACC.24 showed XARELTO reduced the risk of bleeding and net adverse clinical events or rehospitalization

Posted on April 15, 2024

Alexion to present data at AAN 2024 demonstrating how ULTOMIRIS and SOLIRIS can transform outcomes for rare neurological diseases

Posted on April 15, 2024

FASENRA receives approval for treatment of severe asthma in children aged 6 to 11

Posted on April 15, 2024

Pfizer announces their top-line results from phase 3 Study of ABRYSVO in adults with an increased risk of RSV disease

Posted on April 15, 2024

KRAZATI with Cetuximab shows clinically meaningful activity as a targeted treatment option for patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer

Posted on April 15, 2024

Virtuosi has officially become an IACET accredited provider

Posted on April 10, 2024